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ABsTRACT And KEywoRds
Aims. Renal dysfunction is a risk factor for cardiovascular disease, including atrial 
fibrillation (AF) and mortality. However, the exact pathobiology linking different renal 
dysfunction measures, such as albumin excretion or glomerular filtration rate (GFR), to 
cardiovascular- and AF risk are unclear. In this study we investigated the association 
of several renal function measures and incident AF, and whether the relation between 
renal measures and outcomes is modified by AF.
Methods. We examined 8,265 individuals (age 49±13 years, 50% women) included in the 
PREVEND study. We used albumin excretion (morning void and 24-hours urine samples), 
serum creatinine, cystatin C, and Cystatin C-based, creatinine-based, and creatinine-
cystatin C-based GFR as renal function measures.
Results. During a follow-up of 9.8±2.3 years, 267 participants (3.2%) developed AF. In 
the multivariate-adjusted model, GFR, estimated by creatinine, cystatin C, or the com-
bination was not associated with incident AF. However, increased albumin excretion 
was strongly associated with incident AF; urine albumin concentration and excretion 
(HRmorning void 1.10, P=0.005, and HR24-hr collection 1.05, P=0.033) and albumin creatinine ratio 
(HRmorning void 1.05, P=0.010, and HR24-hr collection 1.06, P<0.001). Interaction-terms of incident 
AF and renal measures were not significant for incident cerebrovascular events, periph-
eral vascular events, ischemic heart disease, heart failure and mortality.
Conclusion. In this community-based cohort, increased albumin excretion, and not 
GFR, was associated with incident AF, independent of established cardiovascular risk 
factors. Incidence of AF did not largely alter the association of renal dysfunction and 
cardiovascular outcomes.
Keywords. Atrial fibrillation; Renal function; Epidemiology; Risk factor
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CondEnsEd ABsTRACT
In 8,265 individuals from the community-based PREVEND study, albuminuria was asso-
ciated with incident AF, independent of established cardiovascular risk factors. The as-
sociation between albumin excretion and incident AF was not found for GFR. Incidence 
of AF did not significantly alter the association of renal dysfunction and cardiovascular 
outcomes.
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what’s new
•	 Albuminuria,	a	measure	of	renal	dysfunction,	but	not	GFR,	is	related	to	incidence	of	
AF, independent from other cardiovascular risk factors in the general population.
•	 Albuminuria	can	be	measured	in	first	morning	void	or	24-hour	urine	collection,	the	
association with incident AF was comparable for both methods.
•	 Albumin	 excretion	 can	 be	 used	 in	 those	 with	 and	 without	 incident	 AF	 to	 predict	
cardiovascular events, since the association of renal measures and incident cere-
brovascular events, peripheral vascular events, ischemic heart disease, heart failure, 
and all-cause mortality, was largely similar in those with and without incident AF.
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InTRoduCTIon
Atrial fibrillation (AF) is a common cardiac arrhythmia and is a major public health prob-
lem with an incidence of 1 in 4 for persons over the age of 55 years in the Netherlands.1 
Individuals with AF are at increased risk for cardiovascular complications such as stroke, 
dementia, heart failure, and death.2, 3 Known risk factors and conditions associated with 
AF are advancing age, male sex, diabetes mellitus, hypertension, valve disease, myo-
cardial infarction, heart failure, and obesity.2 More recently, renal dysfunction has also 
been related to incident AF.4, 5 Renal dysfunction is casually related to hypertension, left 
ventricular hypertrophy, inflammation, hypercoagulability, and may activate the renin-
angiotensin-aldosterone system.6 All these mechanisms also increase the susceptibility 
of the development of AF. Thus far, no studies have studied different measures of renal 
function such as serum creatinine or cystatin C, estimated glomerular filtration rates, 
and albumin excretion, in relation to development of AF.
There is abundant data that reduced renal function is associated with increased cardio-
vascular events, in both populations with and without prevalent AF.7, 8 Also in prevalent 
AF populations, renal dysfunction has been associated with increased stroke risk.9 
Whether the relation of renal function and outcomes is modified by AF has not been 
investigated. It has been postulated that in the setting of AF, the associated potential de-
creased cardiac output, potential electrolyte disturbances, changed pharmacokinetics 
of medication used in AF, or associated comorbidities,10 may influence renal measures 
in AF, and potentially its relation with cardiovascular outcome.
Although the exact pathobiology linking renal dysfunction to cardiovascular and AF 
risk are unknown; both albumin excretion and glomerular filtration rates were dem-
onstrated independent markers of cardiovascular risk.11 Albumin excretion is mainly a 
consequence of glomerulus damage, and is considered a marker of systemic vascular 
damage or microvascular disease. The above led to the idea that there may be differ-
ences between renal measures and the association with AF, and that the magnitude of 
effect of renal measures and cardiovascular outcome may be influenced by AF.
METhods
Population. The PREVEND was founded in 1997, and includes a cohort of 8,592 individu-
als, enriched with individuals with a urinary albumin excretion >10ml/L in their morning 
void, since the purpose study was to investigate the natural course of increased levels 
of albuminuria and its relation to cardiovascular and kidney disease.12 In total, 7,786 
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individuals with an urinary albumin excretion >10mg/L and 3,395 individuals with an 
urinary albumin excretion <10mg/L were invited to the PREVEND outpatient clinic. The 
final cohort consisted of 8,592 individuals. At the baseline visit, in addition to detailed 
information about demographics, health behaviours, anthropometric measurements, 
cardiovascular and metabolic risk factors, also blood samples and two 24-hour urine 
samples on 2 consecutive days were collected. For present analysis, we excluded par-
ticipants without any ECG (n=248), and those with prevalent AF (n=79), leaving 8,265 
individuals for analysis. Characteristics and outcomes of the excluded individuals were 
comparable to the included population. The PREVEND study was approved by the insti-
tutional medical Ethics Committee and conducted in accordance with the Declaration of 
Helsinki. All individuals provided written informed consent.
Follow up. The follow-up duration was calculated as the time between the baseline visit 
to the last contact date, death, or December 31, 2008, whichever came first.
Covariate definitions. Systolic and diastolic blood pressures were measured by using 
an automatic Dinamap XL Model 9300 series device, and were calculated as the mean of 
the last two measurements of the two visits. Hypertension was defined as systolic blood 
pressure ≥140 mmHg, diastolic blood pressure ≥90 mmHg, or self-reported use of anti-
hypertensive medication. The ratio of weight to height squared (kg/m2) was used for 
calculation of body mass index (BMI). Obesity was defined as a BMI >30 kg/m2. Diabetes 
mellitus was defined as a fasting plasma glucose >7.0 mmol/L (126 mg/dL), a nonfasting 
plasma glucose >11.1 mmol/L, or use of anti-diabetic medication. Hypercholesterolemia 
was defined as total serum cholesterol above 6.5 mmol/l (251 mg/dl), or serum choles-
terol above 5.0 mmol/l (193 mg/dl) in those with previous myocardial infarction or when 
lipid-lowering medication was used. Smoking was defined as using nicotine within the 
previous year. Alcohol consumption was defined as 2 or more alcoholic drinks per week. 
Previous myocardial infarction or stroke was defined as hospitalization for myocardial 
infarction or stroke for at least 3 days. A committee of heart failure experts adjudicated 
all individuals with heart failure at baseline according to previously published criteria.12 
Peripheral artery disease was defined as an ankle-brachial index <0.9.
Renal measures. Serum cystatin C were determined by nephelometry (BNII, Dade 
Behring Diagnostics, Marburg, Germany). Intra- and interassay coefficients of variation 
were <4.1% and 3.3% for cystatin C. Serum and urine creatinine were determined by 
Kodak Ektachem dry chemistry (Eastman Kodak, Rochester, New York, USA) using an 
automated enzymatic method. The intra- and interassay coefficients of variation of 
serum creatinine were 0.9% and 1.1%.13 The intra- and interassay coefficients of varia-
tion of urine creatinine were 0.9% and 2.9%.14 We defined several GFR measures. The 
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GFR based on serum concentration of creatinine (eGFR-creatinine) was estimated using 
the Simplified Modification of Diet in Renal Disease formula (MDRD). The GFR based on 
serum concentration of cystatin C (eGFR-cystatin C) was estimated with the Chronic Kid-
ney Disease (CKD) Epidemiology Collaboration equation for cystatin C. The GFR based 
on serum concentrations of both creatinine and cystatin C (eGFR-creatinine-cystatin C) 
was estimated using the Epidemiology Collaboration equation for creatinine-cystatin 
C. Urinary albumin was determined by a commercial immunoturbidimetry assay with 
a sensitivity of 2.3 mg/L and interassay and intra-assay coefficients of variation of 4.4% 
and 4.3%, respectively (BNII, Dade Behring Diagnostics, Marburg, Germany). Urine 
albumin concentration was measured in the first morning void. Urine albumin excretion 
was measured in two consecutive 24-hour urine collections, and the average value was 
calculated. Urine albumin-creatinine ratio was calculated based on both the first morn-
ing void and 24-hour urine collections.
Atrial Fibrillation and cardiovascular events during follow up. Incident AF ascertain-
ment has been described in detail previously.2 Briefly, incident AF was diagnosed if 
either atrial flutter or AF was present on a 12-lead ECG obtained at 1 of the 3 PREVEND 
follow-up visits or at an outpatient visit or hospital admission in the 2 hospitals in the 
city of Groningen. For the date of incident AF, the date of the first ECG with a definite 
diagnosis of AF or atrial flutter was used. Information on cardiovascular events was 
obtained from PRISMANT, the Dutch national registry of hospital discharge diagnoses. 
Ischemic heart disease consisted of acute myocardial infarction [ICD code 410], acute 
and subacute ischemic heart disease [ICD 411], coronary artery bypass grafting or percu-
taneous transluminal coronary angioplasty, cerebrovascular events consisted of occlu-
sion or stenosis of the precerebral (ICD 433) or cerebral arteries (ICD 434), subarachnoid 
haemorrhage (ICD 430), and peripheral vascular events consisted of other vascular 
interventions such as percutaneous transluminal angioplasty or bypass grafting of aorta 
and peripheral vessels. A committee of heart failure experts adjudicated all heart failure 
events according to previously published criteria. Data on mortality were obtained 
through the municipal registration.
statistical analysis. A statistical weighting method was used in the prespecified Cox 
proportional-hazards regression analyses, to adjust the overselection of individuals 
with microalbuminuria at baseline, and allow generalization of results to the general 
population. In the weighted Cox regressions, people with urinary albumin excretion <10 
mg/l had a weighing factor of 11.92 and people with urinary albumin excretion >10 mg/l 
had a weighing factor of 1.66. The numbers 11.92 and 1.66 were selected based on the 
unequal inclusion probabilities.
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Individual characteristics were presented as mean ± standard deviation or median 
(range) for continuous variables and counts with percentages for categorical variables. 
We performed 3 prespecified Cox proportional-hazards regression models to relate the 
renal measures to incident AF. Model 1 were univariate analyses, in Model 2, we adjusted 
for established AF risk factors (age, sex, BMI, antihypertensive treatment, previous 
stroke, heart failure, previous myocardial infarction, diabetes, peripheral artery disease, 
smoking, PR-interval duration, NT-proBNP).15 In Model 3 we adjusted for all covariates 
included in Model 2, plus interim myocardial infarction and heart failure, occurring after 
baseline before incident AF. The proportionality assumption was checked by calculat-
ing the Schoenfeld residuals, and where needed time-varying covariates were included 
to avoid proportionality violations. We used Cox time-dependent regression analyses, 
to study whether the association of renal measures and cardiovascular outcome, is 
modified by AF, by including interaction terms of renal measures and AF as time-varying 
covariate. We adjusted for age, sex, heart failure, antihypertensive drug use, diabetes, 
previous stroke, previous myocardial infarction, peripheral artery disease, N-terminal 
prohormone of brain natriuretic peptide (NT-proBNP). All analyses were performed us-
ing R package (version 3.03), and a p-value <0.05 was considered statistically significant.
REsulTs
Individual characteristics. The study sample consisted of 8,265 individuals with mean 
age of 49±13 years, half of them were women. Individual characteristics are shown in 
Table 1. In total, 466 individuals (5.7%) had an estimated creatinine-based GFR<60 ml/
min/1.73m², and 1762 (21.3%) had albuminuria (urinary albumin concentration ≥20 
mg/L).
Renal measures and incident atrial fibrillation. Total follow-up duration was 81,018 
person-years. During a mean follow-up of 9.8 years, 267 (3.2%) individuals developed 
incident AF. None of the GFR measures was associated with incident AF, with no differ-
ences between the GFR based on creatinine, cystatin C or combined method. Albumin 
excretion was strongly associated with incident AF (Table 2). Higher urine albumin con-
centration and albumin creatinine ratio, measured in first morning void samples, were 
associated with an increased risk of incident AF (multivariable-adjusted hazard ratio 
was 1.12 [95% confidence interval (CI) 1.04-1.20] and 1.05 [95% CI 1.00-1.11], respec-
tively). The association remained unchanged after adjustment for interim heart failure 
or myocardial infarction occurring after baseline but before incident AF. A Kaplan Meier 
curve for three groups based on urine albumin concentration (<20, 20-200, and >200 
mg/L) determined in first morning void samples is shown in Figure 1. Also, higher urine 
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albumin excretion and albumin creatinine ratio, determined from 24-hour urine collec-
tions, were associated with an increased risk of incident AF, also after adjustment for 
interim heart failure or myocardial infarction (multivariable-adjusted hazard ratio was 
1.07 [95% CI 1.02-1.11] for urine albumin concentration, and 1.07 [95% CI 1.04-1.10] for 
albumin creatinine ratio). The association remained also unchanged after adjustment 
for interim heart failure or myocardial infarction.
Table 1. Individual characteristics.
Clinical characteristics Total population (n=8265)
Age (years) 49±13
Male sex 4120 (49.8%)
Caucasian 7844 (94.9%)
Smoked 3670 (44.7%)
Alcohol consumption 4873 (59.3%)
Diastolic blood pressure (mmHg) 74±10
Systolic blood pressure (mmHg) 129±20
Peripheral artery disease 291 (3.7%)
BMI (kg/m²) 26±4
Antihypertensive therapy 1098 (16.1%)
NT-proBNP (ng/L) 37 (17-73)
High sensitive CRP (mg/L) 1.3 (0.6-2.9)
Previous stroke 57 (0.7%)
PR-interval duration (ms) 158 (143-172)
Diabetes 310 (3.8%)
Heart rate (bpm) 69±10
Hypercholesterolemia 361 (4.6%)
Hypertension 2237 (27.8%)
Previous myocardial infarction 251 (3.1%)
Heart failure 18 (0.2%)
Renal measures
Serum creatinine (umol/L) 82 (74-92)
Serum cystatin C (mg/dL) 0.77 (0.69-0.87)
eGFR creatinine-based(ml/min/1.73m²) 80 (71-90)
eGFR cystatin- C (ml/min/1.73m²) 100 (85-118)
eGFR creatinine-cystatin-C(ml/min/1.73m²) 91 (80-104)
Urinary albumin concentration(mg/L) 6.9 (4.16-13.03)
Urinary albumin excretion(mg/24hrs) 9.4 (6.3-17.63)
Albumin creatinine ratio(mg/g) 7.0 (4.8-13.0)
Abbreviations: BMI=body mass index; CRP=C-reactive protein; eGFR=estimated glomerular filtration rate; 
NT-proBNP=N-terminal prohormone of brain natriuretic peptide
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Renal measures and incident AF
Relation between renal measures and cardiovascular outcome in atrial fibrillation. 
We studied whether the association of renal function and cardiovascular outcome is 
diff erent in individuals with incident AF versus those without incident AF. We included 
interaction terms of each renal measure and incident AF as time-varying covariate, into 
the regression model. Except for cystatin C, there were no significant interaction terms 
between renal function measures and outcome, implying no diff erent relation between 
renal measure and cardiovascular outcome (Table 3). There was one significant inter-
action between cystatin C and incident AF for the association with the combination of 
cerebrovascular events, peripheral vascular events, ischemic heart disease (hazard ratio 
0.72 [95% CI 0.57-0.91], p=0.007). The hazard ratio of cystatin C to predict the combina-
tion of cerebrovascular events, peripheral vascular events, ischemic heart disease is 
lower in individuals with incident AF compared to those without AF.
Figure 1. Kaplan-Meier estimates of the cumulative incidence of AF, according to three groups of urine 
albumin concentration (<20, 20-200, and >200 mg/L).
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Renal measures and incident AF
dIsCussIon
In present community-based cohort we found that albumin excretion was associated 
with incident AF, and not plasma markers of renal function or GFR. These associations 
were independent of established cardiovascular risk factors, and not mediated via the 
development of heart failure or myocardial infarction during follow up. Furthermore, the 
association of renal measures and incident cerebrovascular events, peripheral vascular 
events, ischemic heart disease, heart failure and all-cause mortality, was largely similar 
in those with and without incident AF.
Renal dysfunction and incident AF. We used both first morning void samples and 24-
hour urine collections, and albumin excretion was predictive for AF, independent of the 
sampling method. The relation between renal dysfunction and risk of AF has been estab-
lished in several cohorts, albeit that not all studies found an association. This may be the 
result of different populations studied, and different measures of renal function used. 
Especially in high-risk populations such as coronary heart disease, or hypertension; 
loss of GFR, measured mainly using creatinine, but also cystatin C has been used, was 
associated with prevalent AF.16 In longitudinal, community-based cohorts the relation 
between GFR and incident AF was less prominent. In elderly included in the Cardiovas-
cular Health Study no relation was found.17 In the Atherosclerosis Risk in Communities 
(ARIC) study and Reasons for Geographic and Racial Differences in Stroke (REGARDS) 
study, however, a relation between GFR and incident AF was found.4, 5 Those studies, 
and others also found a positive relation between albumin excretion measured in the 
first morning void sample and incident AF.4, 5 From prior studies it is known that GFR is 
especially predictive in populations with chronic kidney disease,18 and less predictive 
in the general population with predominantly healthy individuals with normal renal 
function. In the general population, however, albumin excretion is more predictive than 
GFR of future cardiovascular events.19 So, both albumin excretion and GFR are markers 
of renal dysfunction, and as recently demonstrated in a large meta-analysis, both have 
additional value when predicting future cardiovascular events.11 More mechanistically, 
albumin excretion is considered a marker of systemic vascular damage or microvascular 
disease, where GFR is more a marker of kidney disease.11 This may explain our divergent 
findings on albumin excretion and GFR in our community-based cohort. The mechanisms 
underlying the association between renal dysfunction and incident AF, may relate to the 
association of renal dysfunction, and especially albumin excretion, and endothelial dys-
function and hypertension, and is considered a marker of generalized vascular disease.6 
Both clinical and subclinical vascular disease are associated with incident AF. Also, renal 
dysfunction is associated with inflammation and hypercoagulability, and both are a 
known pathophysiological mechanisms involved in development and progression of 
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AF.20 Furthermore, renal dysfunction may activate the renin-angiotensin-aldosterone 
system and lead to salt and water retention, causing left ventricular hypertrophy, and 
subsequent diastolic dysfunction with volume overload of the atria, which in turn may 
lead to AF by atrial dilatation. More studies are needed to determine whether there is a 
direct causal link between renal dysfunction and incident AF.
Renal dysfunction and cardiovascular outcomes. Several studies have shown that 
renal disease measured by a decrease in GFR or increase in albumin excretion are associ-
ated with increased risk of death and cardiovascular events in patients with coronary 
artery disease and in general population.8 There are also studies performed solely in 
patients with AF. In those studies renal dysfunction is associated with an increased risk 
of stroke.9 However, it is unknown whether effect modification by incident AF is present. 
We found no significant interaction between each renal measures and AF when studying 
the combination of cerebrovascular events, peripheral vascular events, ischemic heart 
disease, heart failure and mortality, with one exception. So, we found no robust evi-
dence that the relation between renal measures and cardiovascular outcome is different 
when AF occurs. Therefore, we cannot confirm the postulation by Boriani et al. that in 
AF, the decreased cardiac output, electrolyte disturbances, changed pharmacokinet-
ics, or associated comorbidities,10 may influence the relation between renal measures 
and cardiovascular outcome in AF. This may imply that specific risk prediction models 
including renal measures for populations with and without AF are not necessary.
strengths and limitations. Strengths of our study are the large and contemporary 
community-based cohort, with a detailed clinical and renal assessment and a strong 
validation of incident AF and cardiovascular events. We had in PREVEND a wide range 
of renal measures available; albumin excretion (morning void and 24-hours urine 
samples), serum creatinine, cystatin C, and Cystatin C-based, creatinine-based, and 
creatinine-cystatin C-based GFR.
Most limitations are the result of the observational design of the community-based 
cohort study. Despite the statistical weighting method to adjust for overselection of 
individuals with microalbuminuria at inclusion, our sample may not be completely 
similar to a randomly selected population cohort, and comparisons with other cohorts 
should be made carefully. We may have not captured all asymptomatic paroxysmal AF 
episodes because we did not have continuous ECG recordings. Further, treating physi-
cians were informed about the presence of AF or other undiagnosed cardiovascular 
diseases, treatment was left to the discretion of the physician. We did not have detailed 
information about the AF-related therapies. Data on obstructive sleep apnea, and val-
vular disease were widely captured in our cohort. Since the majority of patients were of 
Chapter 2
Renal measures and incident AF
European ancestry, and had no or only mildly reduced renal dysfunction, results cannot 
be extrapolated to individuals with more impaired renal function, nor to other races 
and ethnicities. Furthermore, the number of individuals with incident AF was modest, 
which reduced our statistical power to detect significant interactions in the secondary 
analyses.
Conclusion. In this community-based cohort, increased albumin excretion, and not 
GFR, was associated with incident AF, independent of established cardiovascular risk 
factors. Presence of AF did not largely alter the association of renal dysfunction and 
cardiovascular outcomes.
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